Most people agree that biotech is the future, and that Big Pharma companies should take an interest if they want to continue to thrive. Sanofi-Aventis has already made inroads into biotech with a $20 billion takeover of Genzyme. And while the deal is a "bet on the future," Genzyme's short-term benefits for Sanofi may be more important, says Jonathan Rockoff on the Wall Street Journal's Health Blog.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

University of California, San Diego, researchers have developed a gene drive to control a fruit-destroying fly.

A new study of a β-thalassemia gene therapy appears promising, according to NPR.

Futurism writes that gene doping could be the next generation of cheating in sports.

In Nature this week: hair color genes, hybridization between 13-year and 17-year cicadas, and more.